Abstract
The expression of metallothionein I/II (MT-I/II) was examined in thyroids of Graves' disease (GD) and nodular goiter (NG) patients to determine its role as a potential marker of proliferation and autoimmune inflammation in the thyroid. MT-I/II and Ki-67 antigen expression was studied using immunohistochemistry in 72 GD and 24 NG patients. MT-I/II expression was noted in the cytoplasm and nuclei of thyrocytes of GD and NG patients. Cytoplasmic and nuclear MT-I/II expression correlated strongly with GD (r=0.51; p<0.0001) and NG (r=0.50; p=0.0137). Cytoplasmic MT-I/II expression was significantly higher in GD (mean IRS 9.24±2.36) than in NG (mean IRS 7.13±2.51; p=0.0006) and correlated positively with Ki-67 antigen expression (r=0.28; p=0.0165). Nuclear MT-I/II expression was elevated in GD (mean 3.53±0.65) in comparison to NG (mean 2.96±0.86; p=0.028). MT-I/II may be a potential marker of GD in the thyroid and may be potentially involved in thyrocytes' proliferation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
